SEC Form 4 · accession 0001209191-16-143182
Juno Therapeutics, Inc. · JUNO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Hans Edgar Bishop
Officer — CEO & President · Director
Period of report
Sep 27, 2016
Accepted (ET)
Sep 29, 2016 · 6:02 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001594864
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Sep 27, 2016 | M | 44,000 | $6.36 | A | 2,490,859 | D | |
| Common StockF1 | Sep 27, 2016 | S | 44,000 | $33.00 | D | 2,446,859 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $6.36 | Sep 27, 2016 | M | 44,000 | D | — | Sep 8, 2024 | Common Stock | 44,000 | 697,506 | D |
Explanation of responses
- F1These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 17, 2016.
- F21/48th of the shares subject to the option became vested and exercisable on October 9, 2014 and 1/48th of the shares subject to the option vested monthly thereafter.